NCT05511714

Expanded Access [11C] Methionine PET Imaging

• Status: Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: St. Jude Children's Research Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: —

Summary

The participants are being asked to get this PET scan because the participants have or may have cancer in the central nervous system (head, neck, or spine), and the investigator and the patient's physician thinks that this scan may provide useful information for the participant's treatment. Primary Objective To provide expanded access to L-\[11C\]methionine as a positron-emitting tracer in children and young adults for the positron emission tomography (PET) imaging of neoplasms of the central nervous system (CNS) and head and neck to guide therapeutic management of disease.

Detailed description

Participants receive an intravenous injection of a small (tracer) dose of L-\[11C\]methionine. Approximately 10 minutes later, patients undergo PET scanning to evaluate localization of the tracer.

Conditions

• Central Nervous System Tumor
• Head and Neck Neoplasms

Interventions

Type	Name	Description
DRUG	L-(11C) methionine	Injected intravenously with 20 mCi/1.7 sq m body surface area of L-\[methyl-11C\]methionine (maximum prescribed dose: 20 mCi).

Timeline

• First posted: 2022-08-23
• Last updated: 2025-10-16

Locations

1 site across 1 country: United States